Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Reports Stock Transactions

Christopher Gibson, CEO of Recursion Pharmaceuticals, reported the sale of 65,000 shares of Class A Common Stock and the conversion of 25,000 shares of Class B Common Stock into Class A Common Stock on March 28, 2024.

Summary

• On March 28, 2024, Christopher Gibson, the CEO of Recursion Pharmaceuticals, engaged in several transactions involving the company's stock.
• He sold 65,000 shares of Class A Common Stock at a price of $10.1 per share.
• He also converted 25,000 shares of Class B Common Stock into Class A Common Stock.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Gibson directly owns 1,043,524 shares of Class A Common Stock and indirectly owns 25,000 shares through the Gibson Family Trust.
• He also indirectly owns 511,000 and 388,000 shares through LAHWRAN-3 LLC and LAHWRAN-4 LLC, respectively.
• Gibson holds options to purchase a total of 1,897,436 shares of Class A Common Stock at various exercise prices and vesting schedules.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports stock transactions by the CEO under a pre-existing trading plan. There's no inherent positive or negative signal.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The sale of shares by the CEO could be for personal financial planning reasons and doesn't necessarily indicate a negative outlook on the company.

Comparison to Industry Standards

• Insider trading activity is closely monitored in the pharmaceutical industry, as it is in other sectors.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also have executives who regularly file Form 4s to report their stock transactions.
• The volume and frequency of these transactions can vary widely depending on individual circumstances and company policies.
• Comparing Gibson's transactions to those of executives at similar-sized biotech companies could provide additional context, but without further information, it's difficult to draw definitive conclusions.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment in the short term, but the existence of a pre-arranged trading plan mitigates this concern.
• The transactions do not appear to have any direct impact on employees, customers, suppliers, or creditors.

Key Dates